Get access

Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil–based protocols. A single-center, prospective, randomized, controlled study

Authors


Tom D. Blydt-Hansen, MD, FRCPC, FE009 – 840 Sherbrook St., Winnipeg, MB R3A 1S1, Canada
Tel.: 204 787 2275
Fax: 204 787 1075
E-mail: tblydthansen@hsc.mb.ca

Abstract

Blydt-Hansen TD, Gibson IW, Birk PE. Histological progression of chronic renal allograft injury comparing sirolimus and mycophenolate mofetil–based protocols. A single-center, prospective, randomized, controlled study.
Pediatr Transplantation 2010: 14:909–918. © 2010 John Wiley & Sons A/S.

Abstract:  In an effort to mitigate progression of IF/TA associated with chronic renal allograft injury, we hypothesize that adjuvant immunosuppression with sirolimus (SRL) will delay progression compared with MMF. Subjects 5–17 yr old, >1-yr post-transplant with mild or moderate IF/TA (Banff criteria) and tacrolimus dose minimization were randomized to continue MMF or convert to SRL and followed for two yr. For the entire cohort (n = 20), there was significant progression of %GGS, ci, ct, cv, and ah scores over the follow-up period (p < 0.05). There was no difference in rates of progression of Banff scores, %GGS, or % IF over two yr between the two groups, though power was low. Both groups exhibited similar rates of eGFR decline (MMF: −12.3 vs. SRL: −11.8 mL/min/1.73 m2/yr), which was correlated with ct score (p < 0.05). The SRL group had more episodes of acute allograft dysfunction and oral ulcers. Proteinuria at 24 months was significantly increased in the SRL group (6/9 subjects) but was not correlated with eGFR or %GGS. We conclude that neither MMF nor SRL, combined with low-dose tacrolimus, was effective at mitigating progressive histological changes or functional decline associated with chronic renal allograft injury.

Ancillary